Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: A phase II trial - Kim, William Y.; Whang, Young E.; Pruthi, Raj S.; Baggstrom, Maria Q.; Rathmell, W. Kimryn; Rosenman, Julian G.; Wallen, Eric M.; Goyal, Lav K.; Grigson, Gayle; Watkins, Catharine; Godley, Paul A. (Urologic oncology, 2011)
Keywords: Adenocarcinoma - drug therapy; Adenocarcinoma - radiotherapy; Adenocarcinoma - surgery; Aged; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Disease Progression; Disease-Free Survival; Docetaxel; Estramustine; Estramustine - administration & dosage; Estramustine - adverse effects; High-risk prostate cancer; Humans; Male; Medical sciences; Middle Aged; Neoadjuvant; Neoadjuvant Therapy - methods; Neoplasm Grading; Neoplasm Staging; Nephrology. Urinary tract diseases; Prostate-Specific Antigen - blood; Prostatectomy; Prostatic Neoplasms - drug therapy; Prostatic Neoplasms - radiotherapy; Prostatic Neoplasms - surgery; Radiotherapy; Taxoids - administration & dosage; Taxoids - adverse effects; Treatment Outcome; Tumors; Tumors of the urinary system; Urinary tract. Prostate gland; Urology; Neoadjuvant; Prostatectomy; Estramustine; Radiotherapy; High-risk prostate cancer; Docetaxel; Antineoplastic agent; High risk; Nephrology; Prostate disease; Early stage; Neoadjuvant treatment; Urology; Extracorporeal irradiation; Cancerology; Surgery; Taxane derivatives; Phase II trial; Antimitotic; Male genital diseases; Urinary system disease; Malignant tumor; Alkylating agent; Nitrogen mustard; Prostate cancer; Localized; Cancer